Clopidogrel treatment group
ApprovedRecruiting 0 watching 0 views this week๐ฅ Hot
85
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Coronary Artery Disease
Conditions
Coronary Artery Disease
Trial Timeline
Mar 22, 2023 โ Dec 31, 2031
NCT ID
NCT05845489About Clopidogrel treatment group
Clopidogrel treatment group is a approved stage product being developed by Yuhan for Coronary Artery Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05845489. Target conditions include Coronary Artery Disease.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05845489 | Approved | Recruiting |
Competing Products
20 competing products in Coronary Artery Disease
Other Products from Yuhan
generic formulation of atorvastatin (Atorvaยฎ) + branded formulation of atorvastatin (Lipitorยฎ)Approved
85
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgApproved
85
Anplag Tab. 100mg bid + Anplag Tab. 100mg tidApproved
85
Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mgApproved
85
Atorvastatin 20mg loading + Atorvastatin 80mg loadingApproved
85